Amarin to showcase data on blockbuster hopeful

Amarin ($AMRN) is gearing up to present data from its successful Phase III study of AMR101 for high triglyceride levels next week in Paris. It's another in a series of data presentations on potential blockbusters this month in the city of love.

With analysts speculating the drug--which is prescription-grade fish oil--potentially hitting $2 billion in annual sales, Amarin is going to show off data from the Phase III MARINE trial. And the presentation, which will take place at the European Society of Cardiology Congress 2011, comes ahead of the company's expected filing for approval of the heart drug this fall.

In November 2010, the company reported the study hit its goal in lowering triglyceride levels from baseline to week 12 in both groups of patients who got 4- and 2-g doses of AMR101. Additionally, the study hit its mark on safety, with no "statistically significant increase in LDL-cholesterol and a safety profile similar to placebo," according to its release.

- see the Amarin release
- here's RTTNews report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.